Netskope Announces Strong Third Quarter Fiscal Year 2026 Financial Results

Netskope Announces Strong Third Quarter Fiscal Year 2026 Financial Results GlobeNewswire December 11, 2025 ARR increased 34% year-over-year to $754 million Q3 revenue increased 33% year-over-year to $184.2 million Surpassed $1 billion in Remaining Performance Obligations, reflecting 41% year-over-year growth Q3 net cash provided by operating activities was $11.2 million, representing 6% of revenue Q3 […]

Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2026 Financial Results

(NasdaqGM:FEIM), MITCHEL FIELD, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the second quarter and fiscal year 2026. Revenue for the three and six months ended October 31, 2025, was approximately $17.1 million and $30.9 million, respectively, compared to $15.8

Ramon Sanchez Joins Firefly Aerospace as Chief Operating Officer

(NasdaqGM:FLY), CEDAR PARK, Texas, Dec. 11, 2025 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, announced it has named Ramon Sanchez as its Chief Operating Officer to drive Firefly's production scaling and operational execution beginning December 22. In this position, Sanchez will be responsible for the company's day-to-day

Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2026 Financial Results

Frequency Electronics, Inc. Announces Second Quarter and Fiscal Year 2026 Financial Results GlobeNewswire December 11, 2025 MITCHEL FIELD, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the second quarter and fiscal year 2026. Revenue for the three and six months

Ramon Sanchez Joins Firefly Aerospace as Chief Operating Officer

Ramon Sanchez Joins Firefly Aerospace as Chief Operating Officer Sanchez will oversee a broader scope as Firefly's COO including the company's day-to-day operations to support company growth GlobeNewswire December 11, 2025 CEDAR PARK, Texas, Dec. 11, 2025 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, announced it has

Tenaya Therapeutics Announces Proposed Public Offering

(NASDAQ:TNYA), SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants

The Islands of Islamorada to Host the 2025 All-Star Fishing Championship, Cementing Its Role as the Premier Luxury Resort in the Florida Keys

Ideal for beachside gatherings, the resort will welcome the biggest names in SFC's professional league, spectators and broadcasters to the Sportfishing Capital of the World From December 10-14, 2025, the world of sportfishing will turn to the Florida Keys as The Islands of Islamoradahosts the All-Stars Sport Fishing Championship, sponsored by AFTCO. The resort, managed

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Toronto, Ontario–(Newsfile Corp. – December 11, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo“) a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

(NasdaqGM:GPCR), SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE(TM)-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

(NASDAQ:TNYA), TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at

Scroll to Top